Wednesday, July 15, 2009

More on immune based therapies for the treatment of cancers

ImmunoCellular Therapeutics Retains Services of Torrey Pines Institute for Molecular Studies and Renowned Immunologist to Evaluate Lead Product Candidate, Business Wire, July 14, 2009. Excerpts:
ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it has retained the services of the Torrey Pines Institute for Molecular Studies in San Diego, CA, to evaluate the immunogenicity of peptides to target cancer stem cells (CSC’s) relating to the Company’s lead product candidate ICT-121. The evaluation will be conducted by Dr. Clemencia Pinilla, a specialist in immune response mechanisms and their role in the prevention and cause of human disease with over 100 publications and multiple patents to her credit.
.....
ICT-121 is IMUC’s cancer stem cell (CSC) vaccine product candidate that consists of a peptide to stimulate a cytotoxic T-lymphocyte (CTL) response to CD133, which is generally overexpressed on the CSCs.
Relevant links: Profile of Clemencia Pinilla, of the Torrey Pines Institute for Molecular Studies in San Diego, California; and, Opinion: A Stem of Hope for Cancer Treatments by Manish Singh (President and CEO of IMUC), Genetic Engineering & Biotechnology News, June 12, 2009. [Previous blog post: Bright future for CSC therapies?, June 14, 2009].

Note that it is important that CSC-targeted vaccination "should not lead to immune reaction to normal cells that may express common antigens". For a recent publication from which this quotation is taken, see: Antigen-Specific T Cell Response from Dendritic Cell Vaccination Using Cancer Stem-like Cell-Associated Antigens by Qijin Xu and 8 co-authors, including John S Yu, Stem Cells 2009(Apr 23) [Epub ahead of print][PubMed Citation]. (John S Yu is Chief Scientific Officer and Chairman of the Board of IMUC, see: Our Team - IMUC).

For some background about immune based therapies for the treatment of cancer, see: Cancer Vaccines by Preeti Gokal Kochar, ProQuest Discovery Guide, January 2006.

See also: Connotea bookmarks matching tag CD133.

Saturday, July 11, 2009

Differentially expressed genes in cell lines of differing lymphatic metastatic ability

Lymphatic metastasis of breast cancer cells is associated with differential gene expression profiles that predict cancer stem cell-like properties and the ability to survive, establish and grow in a foreign environment by Terlika S Pandit and 11 co-authors, including Ann F Chambers and Alan B Tuck, Int J Oncol 2009(Aug); 35(2): 297-308. [FriendFeed entry]. PubMed Abstract:
Although lymphatic dissemination is a major route for breast cancer metastasis, there has been little work to determine what factors control the ability of tumor cells to survive, establish and show progressive growth in a lymph node environment. This information is of particular relevance now, in the era of sentinel lymph node biopsy, where smaller intranodal tumor deposits are being detected earlier in the course of disease, the clinical relevance of which is uncertain. In this study, we compared differentially expressed genes in cell lines of high (468LN) vs. low (468GFP) lymphatic metastatic ability, and related these to clinical literature on genes associated with lymphatic metastatic ability and prognosis, to identify genes of potential clinical relevance. This approach revealed differential expression of a set of genes associated with 'cancer stem cell-like' properties, as well as networks of genes potentially associated with survival and autonomous growth. We explored these differences functionally and found that 468LN cells have a higher proportion of cells with a cancer stem cell-like (CD44+/CD24-) phenotype, have a higher clonogenic potential and a greater ability to survive, establish and grow in a foreign (lymph node and 3D Matrigel) microenvironment, relative to 468GFP cells. Differentially expressed genes which reflect these functions provide candidates for investigation as potential targets for therapy directed against early lymphatic metastasis.

Lecture on stem cells and cancer

The 2009 Summer Symposium of the David H. Koch Institute for Integrative Cancer Research of MIT was on Understanding Metastasis. The Symposium was held on June 19, 2009. One of the lectures in the morning session was on "Stem cells and cancer", by Sean Morrison (University of Michigan) [FriendFeed entry]. A video (35 min) of the lecture can be accessed via the program. One example of a noteworthy slide is the one that's shown for 10 seconds, from 28:38 to 28:48 (entitled: "Nobody has yet tested which cells actually contribute to disease in patients"), in which it's pointed out that the "Fate of cells within patients is unclear ...".

Another lecture, at the same Symposium, addresses this issue (within the context of the theme of the Symposium, "Understanding Metastasis"). It's "Monitoring the fate of cancer cells during metastasis", by Ann Chambers (Regional Cancer Center, London, Ontario). A video (25 min) of her lecture can also be accessed via the program.

Monday, July 6, 2009

CSC as a future avenue of research on breast cancer

Neoadjuvant chemotherapy for early breast cancer by J Sven D Mieog‌ and Cornelis JH van de Velde‌, Expert Opin Pharmacother 2009(Jun); 10(9): 1423-34. [PubMed Citation][ResearchGATE entry][FriendFeed entry]. Last sentence of the abstract:
In the near future, intraoperative fluorescent imaging and targeting of cancer stem cells will become important avenues of research.

Saturday, July 4, 2009

Gordon Conference on Stem Cells and Cancer

The 2009 second Gordon Conference on Stem Cells and Cancer is scheduled for September 13-18, 2009, at Les Diablerets Conference Center, Les Diablerets, Switzerland. Chair: Maarten Van Lohuizen. Vice Chair: Catriona Jamieson. "Applications for this meeting must be submitted by August 23, 2009". [Program][FriendFeed entry].

The first Gordon Conference on Stem Cells and Cancer was held on September 9-14, 2007, at Big Sky Resort, Big Sky, MT, USA.

Friday, July 3, 2009

Therapeutic monoclonal antibody targeting of AML-LSCs

New Targeted Therapy Finds And Eliminates Deadly Leukemia Stem Cells, ScienceDaily July 3, 2009. [FriendFeed entry]. First two sentences:
New research describes a molecular tool that shows great promise as a therapeutic for human acute myeloid leukemia (AML), a notoriously treatment-resistant blood cancer. The study, published in the July 2nd issue of the journal Cell Stem Cell, describes exciting preclinical studies in which a new therapeutic approach selectively attacks human cancer cells grown in the lab and in animal models of leukemia.
This news release is about the article Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells by Liqing Jin and 14 co-authors, including John E Dick and Richard B Lock, Cell Stem Cell 2009(Jul 2); 5(1): 31-42. PubMed Abstract:
Leukemia stem cells (LSCs) initiate and sustain the acute myeloid leukemia (AML) clonal hierarchy and possess biological properties rendering them resistant to conventional chemotherapy. The poor survival of AML patients raises expectations that LSC-targeted therapies might achieve durable remissions. We report that an anti-interleukin-3 (IL-3) receptor alpha chain (CD123)-neutralizing antibody (7G3) targeted AML-LSCs, impairing homing to bone marrow (BM) and activating innate immunity of nonobese diabetic/severe-combined immunodeficient (NOD/SCID) mice. 7G3 treatment profoundly reduced AML-LSC engraftment and improved mouse survival. Mice with pre-established disease showed reduced AML burden in the BM and periphery and impaired secondary transplantation upon treatment, establishing that AML-LSCs were directly targeted. 7G3 inhibited IL-3-mediated intracellular signaling of isolated AML CD34(+)CD38(-) cells in vitro and reduced their survival. These results provide clear validation for therapeutic monoclonal antibody (mAb) targeting of AML-LSCs and for translation of in vivo preclinical research findings toward a clinical application.

Sunday, June 28, 2009

Grant system good at ruling out bad things?

Grant System Leads Cancer Researchers to Play It Safe, by Gina Kolata, The New York Times, June 27, 2009. [Page 1][Page 2][Page 3][FriendFeed entry].

Excerpts from Page 1:
Yet the fight against cancer is going slower than most had hoped, with only small changes in the death rate in the almost 40 years since it [the "war on cancer" initiated by President Nixon in 1971] began.
One major impediment, scientists agree, is the grant system itself. It has become a sort of jobs program, a way to keep research laboratories going year after year with the understanding that the focus will be on small projects unlikely to take significant steps toward curing cancer.
.....
Even top federal cancer officials say the system needs to be changed.
“We have a system that works over all pretty well, and is very good at ruling out bad things — we don’t fund bad research,” said Dr. Raynard S. Kington, acting director of the National Institutes of Health, which includes the cancer institute. “But given that, we also recognize that the system probably provides disincentives to funding really transformative research.”
Excerpt from Page 2:
“They said I don’t have preliminary results,” she said. “Of course I don’t. I need the grant money to get them.”
Excerpt from Page 3:
Some experienced scientists have found a way to offset the problem somewhat. They do chancy experiments by siphoning money from their grants.
Comment: The focus of the article is on the grant funding system for cancer research in the USA. The author, a well-known science journalist, is pessimistic about the success that the current funding system has had in yielding research outputs that have led to any substantial decrease in cancer mortality rates. However, other than briefly mentioning overall cancer mortality rates, she does not attempt to analyze current approaches to cancer control.

In Canada, age-standardized mortality rates, for all cancers and all age groups, have decreased from 248/100,000 in 1984 to 212/100,000 in 2004 (about 15%) for males. In contrast, the corresponding mortality rates for Canadian females were 152/100,000 in 1984 and 147/100,000 in 2004 (a decrease of only about 3%). A detailed analysis is beyond the scope of this brief commentary, but a major reason is that age-standardized mortality rates for respiratory cancers have been higher in males and have been decreasing, while they have been lower in females, and have been increasing.

It has been estimated that, in the USA, "reductions in lung cancer, resulting from reductions in tobacco smoking over the last half century, account for about 40% of the decrease in overall male cancer death rates" (Tobacco Control 2006; 15: 345-347; doi:10.1136/tc.2006.017749). Strong evidence that tobacco smoking and lung cancer rates are related has been available for more than 50 years, since the research work of Richard Doll and Austin Bradford Hill.

We now know a great deal about success stories and best practices for effective, evidence-based tobacco control programs. (See, for example, Success stories and lessons learnt, Tobacco Free Initiative (TFI), World Health Organization).

So, does research play a crucial role in cancer control? Of course it does.

Can it take a very long time for research outputs to have a substantial impact on cancer control? Unfortunately, it can.

Do we have good ways to identify, in advance, areas of transformative research? Unfortunately, no. It can even take a long time to demonstrate that certain research has, indeed, been transformative.

So, what to do? My answer: investment in research is much like investment of venture capital. Only a very small minority of investments yield a big payoff, but one can predict much more easily which investments are likely do badly than which ones are likely to do well.